Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Aclidinium/Formoterol FDC vs Formoterol in COPD
NCT01551888Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2012
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Formoterol Plasma Concentration Versus Time Curve Over Dosing Interval at Steady State at Day 5, Maximum Formoterol Plasma Drug Concentration at Steady State at Day 5 and 1 more. Started Jan 2012; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01551888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551888.